{"ticker": {"uuid": "32082812-2578-4985-b139-2b26c94dc79d", "symbol": "ASBP", "name": "Aspire BioPharma, Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Aspire Bi clarifies public warrant terms after two reverse stock splits; exercise price now $13,800", "summary": "Aspire Biopharma (ASBP) has clarified the terms of its public warrants following two reverse stock splits. The exercise price for these warrants is now $13,800, and the conversion ratio has been adjusted to 1,200 warrants per share of common stock. These changes result from a 1-f", "url": "https://www.tradingview.com/news/tradingview:3bb3c2a667c64:0-aspire-bi-clarifies-public-warrant-terms-after-two-reverse-stock-splits-exercise-price-now-13-800/", "source_name": "TradingView", "published_at": "2026-07-20T21:41:58", "published_display": "20 Jul 2026 21:41", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB(TM)", "summary": "Aspire Biopharma Holdings, Inc.'s subsidiary Buzz Bomb Caffeine Company LC has announced a partnership with multi-time X Games medalist and freestyle motocross legend Jarryd McNeil. McNeil will serve as a global brand ambassador for the BUZZ BOMB\u2122 caffeine product line, integrati", "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/freestyle-motocross-legend-jarryd-mcneil-named-newest-sponsored-athle-1192637", "source_name": "ACCESS Newswire", "published_at": "2026-07-20T12:40:22", "published_display": "20 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin", "summary": "Aspire Biopharma Holdings, Inc. announced its successful participation in CPHI Frankfurt, where it engaged in strategic discussions with global pharmaceutical companies regarding its sublingual high-dose aspirin. The company reported positive final results from an investigational", "url": "https://www.tcpalm.com/press-release/story/10948/aspire-biopharma-engages-with-global-pharmaceutical-leaders-at-cphi-frankfurt-to-advance-partnership-discussions-for-its-sublingual-high-dose-aspirin/", "source_name": "Treasure Coast News", "published_at": "2026-07-11T17:40:29", "published_display": "11 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit", "summary": "Aspire Biopharma's wholly-owned subsidiary, Buzz Bomb Caffeine Company, will showcase its BUZZ BOMB\u2122 sublingual caffeine supplement at The Sports & Active Nutrition Summit USA from February 18-20 in San Diego, CA. The event provides a platform to demonstrate the rapid onset and c", "url": "https://www.independentmail.com/press-release/story/33908/aspire-biopharmas-wholly-owned-subsidiary-buzz-bomb-caffeine-company-to-showcase-buzz-bombtm-caffeine-and-its-innovative-sublingual-delivery-technology-at-the-sports-active-nutrition-summit/", "source_name": "Independent Mail", "published_at": "2026-07-11T07:39:33", "published_display": "11 Jul 2026 07:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTC Markets Life Sciences Investor Forum: Stephen Quesenberry, General Counsel and Director of Product Development, of Aspire Biopharma with Zacks SCR\u2019s David Bautz, PhD", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/otc-markets-life-sciences-investor-103300116.html", "source_name": "Zacks Small Cap Research", "published_at": "2026-07-10T10:33:00+00:00", "published_display": "10 Jul 2026 10:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aspire Biopharma Holdings, Inc. \u2013 BOATS:ASBPW", "summary": "This page provides financial information for Aspire Biopharma Holdings, Inc. (ASBPW), specifically focusing on its forward price-to-earnings ratio. However, the exact financial data for this metric is not displayed, indicating it might be unavailable or requires further navigatio", "url": "https://www.tradingview.com/symbols/BOATS-ASBPW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T03:41:14", "published_display": "10 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Aspire Biopharma Holdings, Inc. \u2013 BOATS:ASBPW", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Aspire Biopharma Holdings, Inc. (ASBPW). Published on TradingView, the content provides a snapshot of this financial ratio for the company, indicating whether the value has changed. The article itself do", "url": "https://www.tradingview.com/symbols/BOATS-ASBPW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T19:09:28", "published_display": "08 Jul 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Aspire Biopharma Holdings, Inc. \u2013 NASDAQ:ASBPW", "summary": "This article displays the \"Price to book forward\" for Aspire Biopharma Holdings, Inc. (NASDAQ: ASBPW) on TradingView. It provides a snapshot of the financial metric without further detailed analysis or historical data. The content is primarily a data point within the financial pl", "url": "https://www.tradingview.com/symbols/NASDAQ-ASBPW/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T20:39:48", "published_display": "07 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Aspire Biopharma Holdings, Inc. \u2013 NASDAQ:ASBP", "summary": "This article provides financial information for Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP), specifically focusing on its price-to-book forward ratio. It notes that the market is currently closed with no trades, and the data is sourced from various financial providers. The pag", "url": "https://www.tradingview.com/symbols/NASDAQ-ASBP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T02:39:36", "published_display": "05 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Aspire Biopharma Holdings, Inc. \u2013 NASDAQ:ASBP", "summary": "This article provides details about Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP), focusing specifically on the number of its shareholders. It indicates that the company's market data is powered by ICE Data Services and FactSet, with SEC filings provided by Quartr. The content a", "url": "https://www.tradingview.com/symbols/NASDAQ-ASBP/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-07-03T22:11:13", "published_display": "03 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASBP - Aspire Biopharma Holdings Inc Earnings", "summary": "This article provides a detailed financial overview of Aspire Biopharma Holdings Inc. (ASBP), including its latest stock performance, market capitalization, key financial ratios, and analyst-related metrics. It highlights the company's recent closing price, percentage change, and", "url": "https://finviz.com/stock?t=ASBP&ta=1&p=w&ty=ea&b=1", "source_name": "Finviz", "published_at": "2026-07-03T22:11:13", "published_display": "03 Jul 2026 22:11", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alois Rubenbauer reports 65,000 shares in Aspire Biopharma (ASBP) Schedule 13G", "summary": "Alois Ryan Rubenbauer III has filed a Schedule 13G, disclosing beneficial ownership of 65,000 shares of Aspire Biopharma Holdings, Inc. (ASBP). This represents 5.0% of the company's common stock, based on 1,295,234 shares outstanding as of March 31, 2026. The filing indicates a p", "url": "https://www.stocktitan.net/sec-filings/ASBP/schedule-13g-aspire-biopharma-holdings-inc-passive-investment-disclos-2d61796ffc94.html", "source_name": "Stock Titan", "published_at": "2026-07-02T12:39:15", "published_display": "02 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Aspire Biopharma Holdings, Inc. \u2013 NASDAQ:ASBP", "summary": "This article provides financial information for Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP), specifically focusing on its Enterprise Value to EBITDA forward metric. The data is presented within the TradingView platform context, indicating market closure and an absence of recen", "url": "https://www.tradingview.com/symbols/NASDAQ-ASBP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T03:11:08", "published_display": "02 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aspire Biopharma Holdings, Inc. \u2013 NASDAQ:ASBP", "summary": "This article provides financial information for Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP), focusing specifically on its forward price-to-earnings ratio. The content is presented within the context of TradingView's platform, indicating that the data is intended for investors ", "url": "https://www.tradingview.com/symbols/NASDAQ-ASBP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T01:40:45", "published_display": "01 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma(ASBP) Stock Options Chain | Quotes & News", "summary": "This article provides access to the stock options chain for Aspire Biopharma (ASBP), along with quotes and news related to the company. It serves as a resource for investors interested in ASBP's options trading, price information, and recent developments.", "url": "https://www.moomoo.com/stock/ASBP-US/options-chain?chain_id=Name1K9-3FXPhg.1l3ors0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A33,%22f%22%3A%22mm%2Fnews%2Fpost%2F19590303%22%7D", "source_name": "Moomoo", "published_at": "2026-06-26T19:39:39", "published_display": "26 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire subsidiary launches caffeine stick packs on Amazon", "summary": "Aspire Biopharma Holdings Inc., through its subsidiary Buzz Bomb Caffeine Company LC, has launched its caffeine stick packs on Amazon's U.S. store. The product offers 50 mg caffeine powder in waterless, sublingual stick packs in various flavors, targeting health-conscious consume", "url": "https://www.investing.com/news/company-news/aspire-subsidiary-launches-caffeine-stick-packs-on-amazon-93CH-4758121", "source_name": "Investing.com", "published_at": "2026-06-24T13:40:48", "published_display": "24 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs", "summary": "Aspire Biopharma's wholly owned subsidiary, Buzz Bomb Caffeine Company LC, has launched its innovative BUZZ BOMB\u2122 50mg caffeine stick packs on Amazon nationwide, offering a waterless, rapid-dissolve caffeine powder. This expansion aims to provide convenient and clean energy alter", "url": "https://www.itemonline.com/aspire-biopharmas-buzz-bomb-tm-launches-on-amazon-introducing-next-generation-caffeine-stick-packs/article_e63e9505-56c9-53a8-b0fb-c6740803c973.html", "source_name": "itemonline.com", "published_at": "2026-06-24T12:40:48", "published_display": "24 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma puts 50 mg caffeine stick packs on Amazon", "summary": "Aspire Biopharma (Nasdaq:ASBP) has launched its BUZZ BOMB\u2122 50 mg caffeine stick packs on Amazon, making them available nationwide. These sublingual, waterless powder packs are designed for rapid energy boosts without the need for water, targeting athletes, professionals, and busy", "url": "https://www.stocktitan.net/news/ASBP/aspire-biopharma-s-buzz-bomb-tm-launches-on-amazon-introducing-next-fdr4am9yy904.html", "source_name": "Stock Titan", "published_at": "2026-06-24T12:40:48", "published_display": "24 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution", "summary": "Aspire Biopharma's wholly owned subsidiary, Buzz Bomb Caffeine Company, has partnered with Blue Shark Beverages to expand the distribution of its BUZZ BOMB\u2122 sublingual caffeine stick packs across Southern California. This strategic agreement, effective February 1, aims to leverag", "url": "https://www.chillicothegazette.com/press-release/story/66843/aspire-biopharmas-wholly-owned-subsidiary-buzz-bomb-caffeine-company-partners-with-blue-shark-beverages-to-expand-southern-california-distribution/", "source_name": "Chillicothe Gazette", "published_at": "2026-06-23T15:39:53", "published_display": "23 Jun 2026 15:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma stockholders approve warrant and share adjustment proposals", "summary": "Aspire Biopharma Holdings, Inc. shareholders recently approved three warrant-related proposals at a special meeting on June 16, 2026. These approvals included authorizing share issuance upon warrant exercise, adjusting the number of exercisable shares, and approving voluntary exe", "url": "https://www.investing.com/news/sec-filings/aspire-biopharma-stockholders-approve-warrant-and-share-adjustment-proposals-93CH-4754417", "source_name": "Investing.com", "published_at": "2026-06-23T00:10:34", "published_display": "23 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Aspire Biopharma Holdings Inc For: 22 June By Investing.com", "summary": "This article announces that Aspire Biopharma Holdings Inc. filed a Form 8K on June 22. The filing is a significant event for the company, as Form 8K is used to notify investors of unscheduled material events or corporate changes. The article itself simply states the filing and pr", "url": "https://ca.investing.com/news/stock-market-news/form-8k-aspire-biopharma-holdings-inc-for-22-june-93CH-4701858", "source_name": "Investing.com Canada", "published_at": "2026-06-22T21:10:35", "published_display": "22 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Holdings Inc (ASBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Aspire Biopharma Holdings Inc (ASBP), detailing", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-asbp/technical", "source_name": "TradingKey", "published_at": "2026-06-18T09:10:13", "published_display": "18 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th", "summary": "Aspire Biopharma Holdings, Inc. announced it will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on June 25th, 2026, at 2:00 pm ET. The event offers an interactive online forum for investors and industry professionals to engage with mana", "url": "https://www.manilatimes.net/2026/06/17/tmt-newswire/globenewswire/aspire-biopharma-to-present-at-the-life-sciences-investor-forum-on-june-25th/2367724/amp", "source_name": "The Manila Times", "published_at": "2026-06-17T23:01:00", "published_display": "17 Jun 2026 23:01", "sentiment": "positive", "sentiment_pct": 78, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Holdings Inc", "summary": "This article provides a brief overview of Aspire Biopharma Holdings Inc. (ASBP), including its market capitalization, current stock price, and P/E TTM. It notes that key revenue breakdown data, both by business segment and by region, have not been disclosed by the company yet. Th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-asbp/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T12:40:45", "published_display": "17 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Holdings Inc (ASBP) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article details the dividend and stock split history for Aspire Biopharma Holdings Inc (ASBP). It notes that the company has not distributed any dividends over the past five years. However, it lists two significant stock split events: a 30-to-1 merger on May 7, 2026, and a 4", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-asbp/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T12:40:44", "published_display": "17 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Acquires Automotive Supplier Dura Driver Control Systems in $30M Deal (ASBP)", "summary": "", "url": "https://finance.yahoo.com/m/af876f24-6e3d-3be4-9c2a-69dc0fb23b3e/aspire-biopharma-acquires.html", "source_name": "InvestorsHub", "published_at": "2026-06-12T14:20:03+00:00", "published_display": "12 Jun 2026 14:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aspire-biopharma-announces-signing-definitive-123000889.html", "source_name": "ACCESS Newswire", "published_at": "2026-06-12T12:30:00+00:00", "published_display": "12 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Stock Is Sliding Today: What's Going On? - Aspire Biopharma Holdings (NASDAQ:ASBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPak5NczVJenlrMmtkTFFlb20xeWo1VzA1Tm1FYXZmTE9waFVHUkViVnZwX0trMjY5SWNWM3pON29mSkFVSlRhWHJlWE1ncFgwb3o3UkZQSGdxX0VVYUVHaWFRVUJYSERXR3V5Zl83QWVpX3Z1RnlMYUtEREt4X1pCcGU5bUxxTVBva0hQYzNUZnN2NnpZdUZmelFOZXVwSGFWT0p3MXdyakVjQlBoSElJNmI4Z1htQQ?oc=5", "source_name": "Benzinga", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Stock Chops After Volatile Spike", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQTjlTVGVrNHl0SFh4YVRsaXFEVTdDOTJkWkhxMWlONmJmQm5NY3Q5OXlfX1VURzBwSjl6Tk5jTXV1ZmhzXzljZVJnRmZrRWl3aThlUDBtdjhBam50cXpTdzFYMzcxZl85RUJ4T2xBNTVFb3cwMU9oemZMcXF6TFVHX2J2Vjc0UQ?oc=5", "source_name": "StocksToTrade", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aspire Biopharma (ASBP) Authorizes $5M Share Repurchase Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQTGktbDFfTm9uT1dLdEktTFlrQURMMTRIT3l2ZWJreGdETEk5MXo0LWZxQlVJcFFmY0F6TmxjVFBESGxIVGtsTVlKd3c5QW0yR3pOTzdhU28zUXZDWnRKZGM2dEk5U2pLNnBKT3psem1LWTlWNU54VXR3YUxMVURCVTQ0QWxBWFhv?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQQlFqV1FTbk11UDNxMEdaaDRJMGRnNkVrcVV0UFhOUEVqbEppbDVhbjRQUm9FVWhmaXdpR3A3SkpucnlPRTh1VXFEM19EZ05FcHd6VndmMXp1b0Z3RlNIdk0xT0ZXMkZXN0FGMUxydFZ3cmpzNVdkOGNySVpBMmtUa0NTN25kRUQ1QVE2X3hBdDhWRTM3cE9EYjUxNGZ0b2Z5Y0hrVzNlY3lpcG1TWWRsWkVtNGNZOS1vWnVrNHBxa05NTVQ5UDBkaFV4RWJXSllsUjFJbkRQOU5VZVZwR0NxMnpwRng?oc=5", "source_name": "ACCESS Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Announces $5.0 Million Share Repurchase Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPYVRuSGE5R0lHdTFUMHZQSWtoLUxOaGNBdXVCRTdUSDlLTWlMZThTUnp4SmFTR09uZmVNWHlaeFluN0tnMUg4OWloaE1xOTctLUtZVTZGOGwtUWYySnBRTUVjM2VwalZHM3ZYdTJrTnpjbWJiN3RrNTdoOUx0bVpfcUx4bXpJUkxXTHV1N01qbjBIcFJ5Tk80S25JclhaYWVr?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNSnRZc0ljaGVFN0h4T2pBTWNNeEdORG9QLVZxUEFyTzQ2Y1RMV3N2UFpYWjZ0MVUwVUttQmNMazJnR0pPUndRU0J5eDB6a2FaSEdTanItYldkb0lNNndyTkdrZ01MaDJCX3hGQmFqX015N3hGQ3VUTXZvOGtHOEpROFpmSHhmNnZrcGdJSk0zUWp0Zw?oc=5", "source_name": "Market source", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNVF9IVm44M0VxNVBwU2U1Yl9sdWM4Vi1fc0RvTmg4X3Z4Q3hDMUdXTlRycHlOVEVwUUZTdTAyQU9SMWZ0VVgyUDJIZVByOWNaRm1zOUNMVUJraThDYjgzekhYN0liRm9VblNqWkMzNjRxcVlIMjBjOEFDbms4YVNzQ3RVZUF0Wnk3S3d3NWhn?oc=5", "source_name": "Market source", "published_at": "2025-06-10T07:00:00+00:00", "published_display": "10 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma (ASBP) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9GeEVSLVd4R0tmb2tsYlM4Ni1DZHJsVGFNcm9tY3ZtMTZqU0p1NUgtNXlReVhwSkxyZ0d3VnFjLTNfd0VWUl90VUlZVDdiblhwT3J3VUU5dkRLQQ?oc=5", "source_name": "MarketBeat", "published_at": "2025-05-31T17:10:24+00:00", "published_display": "31 May 2025 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOcXdPalRQb2I3aFl0YjFodFh3MkhaOTFuTFVBS3g2aE5YZ3lKZHhYb21OU0VMY0tKOEtOMHYwNEtaTzJCdUtMVTljaWc3bDlackFFUXczYXltLTR1QzBJT0k0TzNvQU4zUXJycE1mS2kyT0dFb1FJbVZRZ0NIbzRqYzg2amV6VDV6MGs2eFNn?oc=5", "source_name": "Market source", "published_at": "2025-02-20T08:00:00+00:00", "published_display": "20 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Aspire Bi clarifies public warrant terms after two reverse stock splits; exercise price now $13,800", "summary": "Aspire Biopharma (ASBP) has clarified the terms of its public warrants following two reverse stock splits. The exercise price for these warrants is now $13,800, and the conversion ratio has been adjusted to 1,200 warrants per share of common stock. These changes result from a 1-f", "url": "https://www.tradingview.com/news/tradingview:3bb3c2a667c64:0-aspire-bi-clarifies-public-warrant-terms-after-two-reverse-stock-splits-exercise-price-now-13-800/", "source_name": "TradingView", "published_at": "2026-07-20T21:41:58", "published_display": "20 Jul 2026 21:41", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Freestyle Motocross Legend Jarryd McNeil Named Newest Sponsored Athlete for Aspire Biopharma's BUZZ BOMB(TM)", "summary": "Aspire Biopharma Holdings, Inc.'s subsidiary Buzz Bomb Caffeine Company LC has announced a partnership with multi-time X Games medalist and freestyle motocross legend Jarryd McNeil. McNeil will serve as a global brand ambassador for the BUZZ BOMB\u2122 caffeine product line, integrati", "url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/freestyle-motocross-legend-jarryd-mcneil-named-newest-sponsored-athle-1192637", "source_name": "ACCESS Newswire", "published_at": "2026-07-20T12:40:22", "published_display": "20 Jul 2026 12:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin", "summary": "Aspire Biopharma Holdings, Inc. announced its successful participation in CPHI Frankfurt, where it engaged in strategic discussions with global pharmaceutical companies regarding its sublingual high-dose aspirin. The company reported positive final results from an investigational", "url": "https://www.tcpalm.com/press-release/story/10948/aspire-biopharma-engages-with-global-pharmaceutical-leaders-at-cphi-frankfurt-to-advance-partnership-discussions-for-its-sublingual-high-dose-aspirin/", "source_name": "Treasure Coast News", "published_at": "2026-07-11T17:40:29", "published_display": "11 Jul 2026 17:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit", "summary": "Aspire Biopharma's wholly-owned subsidiary, Buzz Bomb Caffeine Company, will showcase its BUZZ BOMB\u2122 sublingual caffeine supplement at The Sports & Active Nutrition Summit USA from February 18-20 in San Diego, CA. The event provides a platform to demonstrate the rapid onset and c", "url": "https://www.independentmail.com/press-release/story/33908/aspire-biopharmas-wholly-owned-subsidiary-buzz-bomb-caffeine-company-to-showcase-buzz-bombtm-caffeine-and-its-innovative-sublingual-delivery-technology-at-the-sports-active-nutrition-summit/", "source_name": "Independent Mail", "published_at": "2026-07-11T07:39:33", "published_display": "11 Jul 2026 07:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "OTC Markets Life Sciences Investor Forum: Stephen Quesenberry, General Counsel and Director of Product Development, of Aspire Biopharma with Zacks SCR\u2019s David Bautz, PhD", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/otc-markets-life-sciences-investor-103300116.html", "source_name": "Zacks Small Cap Research", "published_at": "2026-07-10T10:33:00+00:00", "published_display": "10 Jul 2026 10:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aspire Biopharma Holdings, Inc. \u2013 BOATS:ASBPW", "summary": "This page provides financial information for Aspire Biopharma Holdings, Inc. (ASBPW), specifically focusing on its forward price-to-earnings ratio. However, the exact financial data for this metric is not displayed, indicating it might be unavailable or requires further navigatio", "url": "https://www.tradingview.com/symbols/BOATS-ASBPW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-10T03:41:14", "published_display": "10 Jul 2026 03:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Aspire Biopharma Holdings, Inc. \u2013 BOATS:ASBPW", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Aspire Biopharma Holdings, Inc. (ASBPW). Published on TradingView, the content provides a snapshot of this financial ratio for the company, indicating whether the value has changed. The article itself do", "url": "https://www.tradingview.com/symbols/BOATS-ASBPW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T19:09:28", "published_display": "08 Jul 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Aspire Biopharma Holdings, Inc. \u2013 NASDAQ:ASBPW", "summary": "This article displays the \"Price to book forward\" for Aspire Biopharma Holdings, Inc. (NASDAQ: ASBPW) on TradingView. It provides a snapshot of the financial metric without further detailed analysis or historical data. The content is primarily a data point within the financial pl", "url": "https://www.tradingview.com/symbols/NASDAQ-ASBPW/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T20:39:48", "published_display": "07 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Aspire Biopharma Holdings, Inc. \u2013 NASDAQ:ASBP", "summary": "This article provides financial information for Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP), specifically focusing on its price-to-book forward ratio. It notes that the market is currently closed with no trades, and the data is sourced from various financial providers. The pag", "url": "https://www.tradingview.com/symbols/NASDAQ-ASBP/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T02:39:36", "published_display": "05 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Aspire Biopharma Holdings, Inc. \u2013 NASDAQ:ASBP", "summary": "This article provides details about Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP), focusing specifically on the number of its shareholders. It indicates that the company's market data is powered by ICE Data Services and FactSet, with SEC filings provided by Quartr. The content a", "url": "https://www.tradingview.com/symbols/NASDAQ-ASBP/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-07-03T22:11:13", "published_display": "03 Jul 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ASBP - Aspire Biopharma Holdings Inc Earnings", "summary": "This article provides a detailed financial overview of Aspire Biopharma Holdings Inc. (ASBP), including its latest stock performance, market capitalization, key financial ratios, and analyst-related metrics. It highlights the company's recent closing price, percentage change, and", "url": "https://finviz.com/stock?t=ASBP&ta=1&p=w&ty=ea&b=1", "source_name": "Finviz", "published_at": "2026-07-03T22:11:13", "published_display": "03 Jul 2026 22:11", "sentiment": "negative", "sentiment_pct": 19, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alois Rubenbauer reports 65,000 shares in Aspire Biopharma (ASBP) Schedule 13G", "summary": "Alois Ryan Rubenbauer III has filed a Schedule 13G, disclosing beneficial ownership of 65,000 shares of Aspire Biopharma Holdings, Inc. (ASBP). This represents 5.0% of the company's common stock, based on 1,295,234 shares outstanding as of March 31, 2026. The filing indicates a p", "url": "https://www.stocktitan.net/sec-filings/ASBP/schedule-13g-aspire-biopharma-holdings-inc-passive-investment-disclos-2d61796ffc94.html", "source_name": "Stock Titan", "published_at": "2026-07-02T12:39:15", "published_display": "02 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Aspire Biopharma Holdings, Inc. \u2013 NASDAQ:ASBP", "summary": "This article provides financial information for Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP), specifically focusing on its Enterprise Value to EBITDA forward metric. The data is presented within the TradingView platform context, indicating market closure and an absence of recen", "url": "https://www.tradingview.com/symbols/NASDAQ-ASBP/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-02T03:11:08", "published_display": "02 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aspire Biopharma Holdings, Inc. \u2013 NASDAQ:ASBP", "summary": "This article provides financial information for Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP), focusing specifically on its forward price-to-earnings ratio. The content is presented within the context of TradingView's platform, indicating that the data is intended for investors ", "url": "https://www.tradingview.com/symbols/NASDAQ-ASBP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T01:40:45", "published_display": "01 Jul 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma(ASBP) Stock Options Chain | Quotes & News", "summary": "This article provides access to the stock options chain for Aspire Biopharma (ASBP), along with quotes and news related to the company. It serves as a resource for investors interested in ASBP's options trading, price information, and recent developments.", "url": "https://www.moomoo.com/stock/ASBP-US/options-chain?chain_id=Name1K9-3FXPhg.1l3ors0&global_content=%7B%22promote_id%22%3A13764,%22sub_promote_id%22%3A33,%22f%22%3A%22mm%2Fnews%2Fpost%2F19590303%22%7D", "source_name": "Moomoo", "published_at": "2026-06-26T19:39:39", "published_display": "26 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire subsidiary launches caffeine stick packs on Amazon", "summary": "Aspire Biopharma Holdings Inc., through its subsidiary Buzz Bomb Caffeine Company LC, has launched its caffeine stick packs on Amazon's U.S. store. The product offers 50 mg caffeine powder in waterless, sublingual stick packs in various flavors, targeting health-conscious consume", "url": "https://www.investing.com/news/company-news/aspire-subsidiary-launches-caffeine-stick-packs-on-amazon-93CH-4758121", "source_name": "Investing.com", "published_at": "2026-06-24T13:40:48", "published_display": "24 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs", "summary": "Aspire Biopharma's wholly owned subsidiary, Buzz Bomb Caffeine Company LC, has launched its innovative BUZZ BOMB\u2122 50mg caffeine stick packs on Amazon nationwide, offering a waterless, rapid-dissolve caffeine powder. This expansion aims to provide convenient and clean energy alter", "url": "https://www.itemonline.com/aspire-biopharmas-buzz-bomb-tm-launches-on-amazon-introducing-next-generation-caffeine-stick-packs/article_e63e9505-56c9-53a8-b0fb-c6740803c973.html", "source_name": "itemonline.com", "published_at": "2026-06-24T12:40:48", "published_display": "24 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma puts 50 mg caffeine stick packs on Amazon", "summary": "Aspire Biopharma (Nasdaq:ASBP) has launched its BUZZ BOMB\u2122 50 mg caffeine stick packs on Amazon, making them available nationwide. These sublingual, waterless powder packs are designed for rapid energy boosts without the need for water, targeting athletes, professionals, and busy", "url": "https://www.stocktitan.net/news/ASBP/aspire-biopharma-s-buzz-bomb-tm-launches-on-amazon-introducing-next-fdr4am9yy904.html", "source_name": "Stock Titan", "published_at": "2026-06-24T12:40:48", "published_display": "24 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution", "summary": "Aspire Biopharma's wholly owned subsidiary, Buzz Bomb Caffeine Company, has partnered with Blue Shark Beverages to expand the distribution of its BUZZ BOMB\u2122 sublingual caffeine stick packs across Southern California. This strategic agreement, effective February 1, aims to leverag", "url": "https://www.chillicothegazette.com/press-release/story/66843/aspire-biopharmas-wholly-owned-subsidiary-buzz-bomb-caffeine-company-partners-with-blue-shark-beverages-to-expand-southern-california-distribution/", "source_name": "Chillicothe Gazette", "published_at": "2026-06-23T15:39:53", "published_display": "23 Jun 2026 15:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma stockholders approve warrant and share adjustment proposals", "summary": "Aspire Biopharma Holdings, Inc. shareholders recently approved three warrant-related proposals at a special meeting on June 16, 2026. These approvals included authorizing share issuance upon warrant exercise, adjusting the number of exercisable shares, and approving voluntary exe", "url": "https://www.investing.com/news/sec-filings/aspire-biopharma-stockholders-approve-warrant-and-share-adjustment-proposals-93CH-4754417", "source_name": "Investing.com", "published_at": "2026-06-23T00:10:34", "published_display": "23 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 8K Aspire Biopharma Holdings Inc For: 22 June By Investing.com", "summary": "This article announces that Aspire Biopharma Holdings Inc. filed a Form 8K on June 22. The filing is a significant event for the company, as Form 8K is used to notify investors of unscheduled material events or corporate changes. The article itself simply states the filing and pr", "url": "https://ca.investing.com/news/stock-market-news/form-8k-aspire-biopharma-holdings-inc-for-22-june-93CH-4701858", "source_name": "Investing.com Canada", "published_at": "2026-06-22T21:10:35", "published_display": "22 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Holdings Inc (ASBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Aspire Biopharma Holdings Inc (ASBP), detailing", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-asbp/technical", "source_name": "TradingKey", "published_at": "2026-06-18T09:10:13", "published_display": "18 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th", "summary": "Aspire Biopharma Holdings, Inc. announced it will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on June 25th, 2026, at 2:00 pm ET. The event offers an interactive online forum for investors and industry professionals to engage with mana", "url": "https://www.manilatimes.net/2026/06/17/tmt-newswire/globenewswire/aspire-biopharma-to-present-at-the-life-sciences-investor-forum-on-june-25th/2367724/amp", "source_name": "The Manila Times", "published_at": "2026-06-17T23:01:00", "published_display": "17 Jun 2026 23:01", "sentiment": "positive", "sentiment_pct": 78, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Holdings Inc", "summary": "This article provides a brief overview of Aspire Biopharma Holdings Inc. (ASBP), including its market capitalization, current stock price, and P/E TTM. It notes that key revenue breakdown data, both by business segment and by region, have not been disclosed by the company yet. Th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-asbp/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T12:40:45", "published_display": "17 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Holdings Inc (ASBP) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article details the dividend and stock split history for Aspire Biopharma Holdings Inc (ASBP). It notes that the company has not distributed any dividends over the past five years. However, it lists two significant stock split events: a 30-to-1 merger on May 7, 2026, and a 4", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-asbp/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T12:40:44", "published_display": "17 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Acquires Automotive Supplier Dura Driver Control Systems in $30M Deal (ASBP)", "summary": "", "url": "https://finance.yahoo.com/m/af876f24-6e3d-3be4-9c2a-69dc0fb23b3e/aspire-biopharma-acquires.html", "source_name": "InvestorsHub", "published_at": "2026-06-12T14:20:03+00:00", "published_display": "12 Jun 2026 14:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aspire-biopharma-announces-signing-definitive-123000889.html", "source_name": "ACCESS Newswire", "published_at": "2026-06-12T12:30:00+00:00", "published_display": "12 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Stock Is Sliding Today: What's Going On? - Aspire Biopharma Holdings (NASDAQ:ASBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPak5NczVJenlrMmtkTFFlb20xeWo1VzA1Tm1FYXZmTE9waFVHUkViVnZwX0trMjY5SWNWM3pON29mSkFVSlRhWHJlWE1ncFgwb3o3UkZQSGdxX0VVYUVHaWFRVUJYSERXR3V5Zl83QWVpX3Z1RnlMYUtEREt4X1pCcGU5bUxxTVBva0hQYzNUZnN2NnpZdUZmelFOZXVwSGFWT0p3MXdyakVjQlBoSElJNmI4Z1htQQ?oc=5", "source_name": "Benzinga", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Stock Chops After Volatile Spike", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxQTjlTVGVrNHl0SFh4YVRsaXFEVTdDOTJkWkhxMWlONmJmQm5NY3Q5OXlfX1VURzBwSjl6Tk5jTXV1ZmhzXzljZVJnRmZrRWl3aThlUDBtdjhBam50cXpTdzFYMzcxZl85RUJ4T2xBNTVFb3cwMU9oemZMcXF6TFVHX2J2Vjc0UQ?oc=5", "source_name": "StocksToTrade", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma (ASBP) Authorizes $5M Share Repurchase Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQTGktbDFfTm9uT1dLdEktTFlrQURMMTRIT3l2ZWJreGdETEk5MXo0LWZxQlVJcFFmY0F6TmxjVFBESGxIVGtsTVlKd3c5QW0yR3pOTzdhU28zUXZDWnRKZGM2dEk5U2pLNnBKT3psem1LWTlWNU54VXR3YUxMVURCVTQ0QWxBWFhv?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxQQlFqV1FTbk11UDNxMEdaaDRJMGRnNkVrcVV0UFhOUEVqbEppbDVhbjRQUm9FVWhmaXdpR3A3SkpucnlPRTh1VXFEM19EZ05FcHd6VndmMXp1b0Z3RlNIdk0xT0ZXMkZXN0FGMUxydFZ3cmpzNVdkOGNySVpBMmtUa0NTN25kRUQ1QVE2X3hBdDhWRTM3cE9EYjUxNGZ0b2Z5Y0hrVzNlY3lpcG1TWWRsWkVtNGNZOS1vWnVrNHBxa05NTVQ5UDBkaFV4RWJXSllsUjFJbkRQOU5VZVZwR0NxMnpwRng?oc=5", "source_name": "ACCESS Newswire", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Announces $5.0 Million Share Repurchase Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPYVRuSGE5R0lHdTFUMHZQSWtoLUxOaGNBdXVCRTdUSDlLTWlMZThTUnp4SmFTR09uZmVNWHlaeFluN0tnMUg4OWloaE1xOTctLUtZVTZGOGwtUWYySnBRTUVjM2VwalZHM3ZYdTJrTnpjbWJiN3RrNTdoOUx0bVpfcUx4bXpJUkxXTHV1N01qbjBIcFJ5Tk80S25JclhaYWVr?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxNSnRZc0ljaGVFN0h4T2pBTWNNeEdORG9QLVZxUEFyTzQ2Y1RMV3N2UFpYWjZ0MVUwVUttQmNMazJnR0pPUndRU0J5eDB6a2FaSEdTanItYldkb0lNNndyTkdrZ01MaDJCX3hGQmFqX015N3hGQ3VUTXZvOGtHOEpROFpmSHhmNnZrcGdJSk0zUWp0Zw?oc=5", "source_name": "Market source", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNVF9IVm44M0VxNVBwU2U1Yl9sdWM4Vi1fc0RvTmg4X3Z4Q3hDMUdXTlRycHlOVEVwUUZTdTAyQU9SMWZ0VVgyUDJIZVByOWNaRm1zOUNMVUJraThDYjgzekhYN0liRm9VblNqWkMzNjRxcVlIMjBjOEFDbms4YVNzQ3RVZUF0Wnk3S3d3NWhn?oc=5", "source_name": "Market source", "published_at": "2025-06-10T07:00:00+00:00", "published_display": "10 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma (ASBP) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE9GeEVSLVd4R0tmb2tsYlM4Ni1DZHJsVGFNcm9tY3ZtMTZqU0p1NUgtNXlReVhwSkxyZ0d3VnFjLTNfd0VWUl90VUlZVDdiblhwT3J3VUU5dkRLQQ?oc=5", "source_name": "MarketBeat", "published_at": "2025-05-31T17:10:24+00:00", "published_display": "31 May 2025 17:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxOcXdPalRQb2I3aFl0YjFodFh3MkhaOTFuTFVBS3g2aE5YZ3lKZHhYb21OU0VMY0tKOEtOMHYwNEtaTzJCdUtMVTljaWc3bDlackFFUXczYXltLTR1QzBJT0k0TzNvQU4zUXJycE1mS2kyT0dFb1FJbVZRZ0NIbzRqYzg2amV6VDV6MGs2eFNn?oc=5", "source_name": "Market source", "published_at": "2025-02-20T08:00:00+00:00", "published_display": "20 Feb 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 45, "sentiment_summary": {"positive": 9, "negative": 3, "neutral": 33, "score": 53, "total": 45, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 13.0, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 7.01, "count": 15}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 1.1, "count": 2}], "positive_events": 9, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 6.24, "latest_week": "2026-07-17", "one_week_move": 3.8, "four_week_move": -5.2, "twelve_week_move": 1.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.497942, "market_dynamics_buy_signal": false, "relative_strength": -97.083642, "fair_value_gap": -99.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 43.278, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+3.8% over one week, -5.2% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "TradingView", "count": 9}, {"label": "ACCESS Newswire", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "Stock Titan", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "simplywall.st", "count": 2}, {"label": "Treasure Coast News", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 36}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 15}, {"label": "Deals and strategy", "count": 3}, {"label": "Regulatory and legal", "count": 2}, {"label": "Capital return", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "36", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+3.8% over one week, -5.2% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Aspire Bi clarifies public warrant terms after two reverse stock splits; exercise price now $13,800"}], "updated_at": "2026-07-22T03:05:29.597117+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}